The market split Wednesday as a historic biotech rally overpowered another weak technology session.

Moderna nearly tripled after delivering the first positive Phase 3 result for a personalized mRNA cancer vaccine, sending Merck to a record and health care sharply higher. Treasury support cooled the bond selloff, but Fed minutes showed broader support for rate hikes and concern that AI spending is creating inflation before productivity.

Stocktwits skipped the megacaps and piled into $MRNA, $BULL, $NVAX, $IOVA, and $PURR. The live debate was whether scientific breakthroughs and record growth justified the chase, or whether momentum had already outrun the numbers.

Today's Briefing: Powered by Stocktwits Community API.

Moderna did not cure cancer Wednesday, but its stock climbed like it did. The firm demonstrated the first positive Phase 3 result for a personalized mRNA cancer vaccine, nearly tripling the stock, also sending Merck to a record, and turning oncology into the market’s loudest momentum trade.

“I have a feeling that this is just the beginning of a new field,” Jane Healy, Merck vice president of oncology, told The Wall Street Journal.

The RIP: $MRNA ( ▲ 176.97% ) rocketed 177% on 186.2M shares, or 33.7x recent pace, while $MRK jumped 12.6%. $BNTX gained 22%, $TEM added 24.1%, $LLY rose 4.5%, and $XBI climbed 5.9%.

The 1,137-patient trial tested Moderna’s tumor-specific intismeran vaccine with Merck’s Keytruda after high-risk melanoma had been surgically removed. The combination delayed recurrence and distant spread versus just using Keytruda alone, but the companies withheld the actual Phase 3 hazard ratios until a medical meeting later this year.

“The stocks are reacting like you’re going to use this vaccine after every surgery in cancer, and I think that’s a massive overreach,” Leerink Partners analyst Daina Graybosch told The Wall Street Journal.

Wall Street bought the whole cancer-science project anyway. Alot of biotech caught the upside. If the full data cannot justify Wednesday’s valuation reset, the market will rediscover that personalized vaccines are considerably harder to manufacture than rocket emojis. All in all though, a great day.

The Community Read: The $MRNA stream is neutral after the moonshot, see who cashed out ->

Prenetics (NASDAQ: PRE), the parent company of IM8, co-founded by David Beckham, raises full-year guidance to $220–230M revenue — with FY2027 initiated at $400M+, nearly doubling again. Consolidated cash flow expected to turn positive in Q3.

Prenetics reported record Q2 revenue of $46.5M — IM8 up 33% sequentially, ~4.5x year over year.

July was the biggest month in company history: $20.9M, a ~$251M annualized run-rate.

General Catalyst committed $1 billion of growth financing on July 14.

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

Target gave the retail aisle a fresh plot twist Wednesday. The big-box chain raised its annual sales outlook after shoppers finally returned, while TJX stumbled on execution problems, Lowe’s rewarded a messy beat, and Walmart waited at Thursday’s checkout.

The RIP: $TGT ( ▲ 4.28% ) gained 4.3%, $LOW rose 2.3%, $TJX fell 4.1%, and $WMT slipped 0.8%. Target reported $4.11 EPS on $26.54B in revenue, with comparable sales up 3.8%, traffic up 3.6%, and digital comps up 8.7%.

Target now expects roughly 5% full-year sales growth, up from 4%, but a nearly $1B tariff refund contributed about $1.65 per share to quarterly profit. The operating signals were cleaner than the headline EPS: more shoppers visited, same-day delivery grew, and management’s price cuts helped win back demand.

Walmart reports before Thursday’s open, with Wall Street expecting $0.74 EPS, $186.62B in sales, and 3.8% comparable-sales growth. The Community Read: The $TGT room is bullish on the turnaround, test the traffic gains ->

Estée Lauder shares jumped Wednesday after the prestige-beauty giant capped its turnaround year with strong results, and raised its fiscal 2027 profitability outlook. Skin care, fragrance, China, travel retail, and online sales helped Estée Lauder return to growth after three annual revenue declines.

The RIP: $EL ( ▲ 16.31% ) climbed 16.3% on 13.6M shares, five times its recent pace. Adjusted EPS reached $0.39 on $3.64B in quarterly revenue. Fiscal 2026 net sales rose 5% to $15.05B, organic sales grew 3%, adjusted EPS increased 66%, and operating margin expanded 320 basis points. Management expects 3% to 5% organic sales growth in fiscal 2027, with restructuring projected to deliver $1.2B in annual gross benefits.

The OpenAI and Anthropic IPOs’ are arriving soon, likely in the fall and winter before the year is up, and tech Twitter, my doomscrolling dirty pleasure, is filled with talk. This week features doomer posting about OpenAI, as anyone worth their influencer payouts yells out ‘bubble’ to gain engagement.

OpenAI recently told investors about its revenue, WSJ learned, and the numbers were not great.

The RIP: OpenAI’s Q2 revenue rose 18% to $6.7B from $5.7B, while its operating loss widened to $12.3B from $9.3B. Meanwhile Anthropic’s revenue more than doubled to $11.6B, overtaking OpenAI for the first time, and it reported a small adjusted operating profit.

Look, $7B is great for most companies, just not for generation defining trillions of dollars in datacenter-hoarding companies. Operating loss was near $9.3B in Q1, up to $12.3B in Q2, pacing faster than growth.

Then came a tweet from Sam Alt-Man himself, that said the firm was pausing its development of the next best model, just for two weeks, for security concerns. I found the tweet by way of a tech reporter parroting the words, ‘we are pausing our crazy spend on AI so we can hype up our revenue for our IPO, we love money, and we know the rest of the industry will join us to keep the grift going.’ Or something to that effect.

24.4K WATCHERS · BULLISH · NORMAL ACTIVITY

Webull reported record quarterly revenue of $198.8M, up 51%, while adjusted operating profit reached $62.6M and customer assets jumped 79%. The brokerage delivered the growth traders wanted, but the bullish room is still deciding how much of Robinhood’s valuation premium Webull actually deserves.

20.2K WATCHERS · NEUTRAL · LOW ACTIVITY

Wolfspeed fell after hours despite beating loss expectations, as quarterly revenue declined to $149.6M and the company recorded a $145.4M net loss. AI data-center revenue more than doubled, but the neutral room is weighing that growth against another quarter of heavy losses and a $140M to $160M revenue outlook.

28.9K WATCHERS · BEARISH · LOW ACTIVITY

BitMine surged with Ethereum after disclosing earlier this week that its treasury reached 5.82M ETH, roughly 4.8% of the token’s circulating supply. The company is approaching its 5% ownership target, but the bearish room remains focused on dilution, treasury valuation, and how quickly crypto gains can reverse.

Bearish 🐻 | Bullish 🐮 | It’s Complicated 😵‍💫

Short-term market moves are unpredictable. But longer-term setups tend to develop in plain sight… That is, if you’re willing to look past the next headline.

Our analysts believe the next generation of market leaders (think Apple, Google, Tesla) is forming now… And they’ve identified the 7 companies that fit the “Magnificent 7” pattern

Instead of asking what might move this quarter, our analysts asked a different question: Which companies are building the foundation to be market giants two years from now?

The result is a free report with a forward-looking list focused on durability, scale, and growth paths that take time to play out. These are positions designed for investors who think in cycles, not weeks. Don’t wait until everyone’s talking about them. Take a look at the companies our analysts believe are aligned with the market’s next phase while you still can.

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

💰 ‘I Want Things To Always Be Right Between Us,’ Natalie Harp Reportedly Wrote To Trump

🌎 Treasury Department to double debt buybacks after bond yield spike

📊 SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA Moment

🪙 Bitcoin surges above $68,000, liquidating $1.4 billion shorts as Treasury buybacks boost risk appetite

🧬 Trump taps White House adviser Heidi Overton to lead FDA

Macro: Weekly jobless claims (8:30 AM ET). 📊
Pre-Market Earnings: $WMT Walmart Inc, $KNDI Kandi Technologies Group Inc, $CAN Canaan Inc - ADR, $BLRX Bioline Rx Ltd - ADR, $DE Deere & Co., +14 more. ☀️
After-Market Earnings: $ROST Ross Stores, Inc., $FLUX Flux Power Holdings inc, $FINV FinVolution Group - ADR. 🌙P.S. You can listen to all of these earnings calls on Stocktwits.

Want to see some change? Email me, Kevin Travers, with feedback, and follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎

_{Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The content is to be used for informational and entertainment purposes only and the service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which content is published on the service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍
Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋}